ClinicalTrials.gg
CompletedNCT07015671Updated Mar 6, 2026

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

A Phase 3 interventional study of 10 mg Torsemide tablet and 25 mg Aldactone (Spironolactone) tablet in Bioequivalence Study in Healthy Subjects and PK/PD, sponsored by Sarfez Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Sarfez Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects.

Read the detailed description

Screening and Study Assessments Demographic data, medical, surgical and medication histories, physical examination, height, weight and BMI as well as 12 lead ECG, chest X-ray [PA view], vital signs [blood pressure, pulse rate, respiratory rate and oral temperature], Oxygen Saturation (SpO2 %), hematology, biochemistry, HIV 1 \& 2, Hepatitis B and C, RPR test for Syphilis and urinalysis will be done at screening. Females will undergo a serum pregnancy test at the time of screening.

Urine drug screen and breath alcohol test will be done prior to each check-in. Urine pregnancy test will be performed for females prior to each check-in.

Study Duration The total expected study duration is at least 27 days from the day of check-in for Period 1 to the end of Period 4. In case of any post-study laboratory parameter abnormalities, the subject will be followed up at the investigator's discretion.

Washout Period A washout period of at least 07 days will be maintained in between the periods.

Housing Subjects will be housed in the facility from at least 36 hours prior to day of dosing until at least 72 hours post-dose in each period.

Treatments

Treatments Administered:

Treatment (A): 10 mg Torsemide tablet Dose: 1x 10 mg tablet Route of Administration: Oral

Treatment (B): 25 mg Aldactone® (Spironolactone) tablet Dose: 1x 25 mg tablet Route of Administration: Oral

Treatment (C): FDC (12 mg ER Torsemide + 15 mg Spironolactone) tablet. Dose: 1x (12 mg + 15 mg) FDC tablet Route of Administration: Oral

Treatment (D): 10 mg Torsemide tablet and 25 mg Aldactone® (Spironolactone) tablet given together Dose: 1x 10 mg Torsemide tablet + 1x 25 mg Spironolactone tablet Route of Administration: Oral

Blood and Urine Sampling

All subjects will be given a labeled container for urine collection in each period.

Blood samples will be collected in each period.

Adverse and serious adverse events will be monitored throughout the study.

02

Conditions studied

  • Bioequivalence Study in Healthy Subjects
  • PK/PD

Keywords

  • torsemide
  • Spironolactone
  • bioequivalence
  • diuresis
  • extended release
  • immediate release
  • PK/PD
03

In context

Lead sponsor

Sarfez Pharmaceuticals, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must fulfill all of the following criteria to be considered for inclusion into this study:

  1. Healthy human adult subjects within the age range of 18 to 45 years [both inclusive].
  2. Weight not less than 50 kg for male and 45 kg for female and 18.50 to 29.99 kg/m2 [both inclusive].
  3. Willingness to provide written to participate in the study.
  4. Subjects should be non-smoker [defined as someone who has stopped smoking for a year before the date of screening] and should not be consuming tobacco containing products.
  5. Free of significant diseases or abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead , Chest X-ray [PA view].
  6. Absence of disease markers of 1 and 2, and C and Syphilis.
  7. Subject should be literate.
  8. Male subjects must be using two acceptable methods of (e.g., spermicidal gel plus condom) for the entire duration of the study, and upto the study completion visit. Subjects must refrain from fathering a child in the next two weeks following the last study drug administration or have undergone vasectomy (vasectomy must have been done more than 6 months prior to first dosing). Contraceptive usage requirement will be conveyed during the inform consent process. Subjects will be advised to follow effective method of contraception until 2 weeks after the last dose is given.
  9. Female subjects of must be using two acceptable methods of contraception, (e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study and for two weeks following the last study drug administration. Contraceptive usage requirement will be conveyed during the inform consent process (or) women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).

Exclusion criteria

Exclusion Criteria:

Any of the following conditions are cause for exclusion from the study:

  1. History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, psychiatric disease/disorder.
  2. History or presence of significance:

    Asthma, urticaria, or other allergic-type reactions after taking Torsemide, Spironolactone or any other drug. Ulceration or history of gastric and/or duodenal ulcer. Stomach or intestinal bleeding. Jaundice in the past 6 months. Internal bleeding.

  3. or allergy to Torsemide, Spironolactone or any of the .
  4. History of alcohol or drug abuse in the past one year.
  5. Family history of bleeding disorders.
  6. History of difficulty in passing urine or emptying the bladder or of incontinence.
  7. Have donated 500 mL or more blood within 90 days before receiving the first dose of the study drug.
  8. Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study.
  9. Any difficulty in the accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood.
  10. Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period.
  11. Refuse to abstain from fluid for at least 1 h before and 1 h after dosing in each period (except 240 ± 2 mL water given for dosing).
  12. Found positive during breath alcohol test done during period one check-in and inability to abstain from alcohol till the end of the study.
  13. Found positive during urine drug screening done prior to period one check-in.
  14. Found positive screening results for , , , or Syphilis.
  15. History of difficulty in swallowing tablets.
  16. Received any medication [including over-the-counter products], herbal products for 14days preceding the study.
  17. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
  18. History of dehydration from diarrhea, vomiting, or any other reason within 24 hours prior to check-in of period one.
  19. Consumption of xanthine-containing food and beverages (chocolates, tea, coffee, or cola drinks) for at least 48 hours prior to check-in of period one.
  20. Consumption of grapefruit or its products within the 48 hours prior to check-in of period one.
  21. Female subjects are found to be positive during pregnancy tests done prior to period one check-in.
  22. Lactating females.
  23. Investigator/Physician feels that it is not in the subject's and/or study's best interest to enroll the subject.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A

    10 mg Torsemide tablet

    Drug: 10 mg Torsemide tablet

  • Experimental
    Treatment B

    25 mg Aldactone (Spironolactone) tablet

    Drug: 25 mg Aldactone (Spironolactone) tablet

  • Experimental
    Treatment C

    FDC (12 mg ER Torsemide + 15 mg Spironolactone) tablet

    Drug: FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet

  • Experimental
    Treatment D

    10 mg Torsemide tablet and 25 mg Aldactone® (Spironolactone) tablet given together

    Drug: 10 mg Torsemide tablet · Drug: 25 mg Aldactone (Spironolactone) tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence and bioavailability of the FDC to each of its components

    Compare bioequivalence and bioavailability (BE and BA) of the FDC to each of the components of the FDC, administered either individually or together: 10 mg Torsemide alone, 25 mg Spironolactone alone and 10 mg Torsemide and 25 mg Spironolactone taken together. Torsemide, Spironolactone, and Canrenone data will be used to estimate the following: Primary pharmacokinetic parameters: Cmax, AUC0-t and AUC0-inf.

    Time frame: Through study completion: at least 27 days with minimum 7 days washout periods between testing

  2. Urinary torsemide excretion

    Urinary torsemide excretion: Rmax, Ae0-24, tmax and percentage drug recovered.

    Time frame: Through study completion: at least 27 days with minimum 7 days washout periods between testing

07

Study locations

1 site
  • Sarfez Pharmaceuticals
    Vienna, Virginia 22182, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 11, 2025
StartActual
Jul 1, 2025
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07015671
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jul 1, 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Mar 6, 2026

Study contacts

Salim Shah, PhD, JD
study chair · Sarfez Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torsemide · Spironolactone

Start the discussion